|
1.
|
Shih IeM and Kurman RJ: Ovarian
tumorigenesis: a proposed model based on morphological and
molecular genetic analysis. Am J Pathol. 164:1511–1518. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Pignata S and Vermorken JB: Ovarian cancer
in the elderly. Crit Rev Oncol Hematol. 49:77–86. 2004. View Article : Google Scholar
|
|
3.
|
Boren T, Xiong Y, Hakam A, et al:
MicroRNAs and their target messenger RNAs associated with ovarian
cancer response to chemotherapy. Gynecol Oncol. 113:249–255. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Zhao H, Ding Y, Tie B, et al: miRNA
expression pattern associated with prognosis in elderly patients
with advanced OPSC and OCC. Int J Oncol. 43:839–849.
2013.PubMed/NCBI
|
|
5.
|
Malpica A, Deavers MT, Tornos C, et al:
Interobserver and intraobserver variability of a two-tier system
for grading ovarian serous carcinoma. Am J Surg Pathol.
31:1168–1174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Hannibal CG, Vang R, Junge J,
Kjaerbye-Thygesen A, Kurman RJ and Kjaer SK: A binary histologic
grading system for ovarian serous carcinoma is an independent
prognostic factor: a population-based study of 4317 women diagnosed
in Denmark 1978–2006. Gynecol Oncol. 125:655–660. 2012.PubMed/NCBI
|
|
7.
|
Lu D, Kuhn E, Bristow RE, et al:
Comparison of candidate serologic markers for type I and type II
ovarian cancer. Gynecol Oncol. 122:560–566. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Gloss BS and Samimi G: Epigenetic
biomarkers in epithelial ovarian cancer. Cancer Lett. 342:257–263.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kurman RJ, Visvanathan K, Roden R, Wu TC
and Shih IeM: Early detection and treatment of ovarian cancer:
shifting from early stage to minimal volume of disease based on a
new model of carcinogenesis. Am J Obstet Gynecol. 198:351–356.
2008.PubMed/NCBI
|
|
10.
|
Vang R, Shih I and Kurman RJ: Ovarian
low-grade and high-grade serous carcinoma: pathogenesis,
clinicopathologic and molecular biologic features, and diagnostic
problems. Adv Anat Pathol. 16:267–282. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kurman RJ and Shih I: Molecular
pathogenesis and extraovarian origin of epithelial ovarian
cancer-shifting the paradigm. Hum Pathol. 42:918–931. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Neelakandan K, Babu P and Nair S: Emerging
roles for modulation of microRNA signatures in cancer
chemoprevention. Curr Cancer Drug Targets. 12:716–740. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Li C, Hashimi SM, Good DA, et al:
Apoptosis and microRNA aberrations in cancer. Clin Exp Pharmacol
Physiol. 39:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang Y, Wang Q, Zhao Y, et al: Protective
effects of estrogen against reperfusion arrhythmias following
severe myocardial ischemia in rats. Circ J. 74:634–643. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Li ZD, Hu XW, Wang YT and Fang J: Apigenin
inhibits proliferation of ovarian cancer A2780 cells through Id1.
FEBS Lett. 583:1999–2003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Schick B, Wemmert S, Jung V, Steudel WI,
Montenarh M and Urbschat S: Genetic heterogeneity of the MYC
oncogene in advanced juvenile angiofibromas. Cancer Genet
Cytogenet. 164:25–31. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Seidman JD and Kurman RJ:
Subclassification of serous borderline tumors of the ovary into
benign and malignant types. A clinicopathologic study of 65
advanced stage cases. Am J Surg Pathol. 20:1331–1345. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Smith Sehdev AE, Sehdev PS and Kurman RJ:
Noninvasive and invasive micropapillary (low-grade) serous
carcinoma of the ovary: a clinicopathologic analysis of 135 cases.
Am J Surg Pathol. 27:725–736. 2003.PubMed/NCBI
|
|
19.
|
Lalwani N, Prasad SR, Vikram R, Shanbhogue
AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic
features of ovarian cancers: implications for diagnosis and
treatment. Radiographics. 31:625–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Malpica A, Deavers MT, Lu K, et al:
Grading ovarian serous carcinoma using a two-tier system. Am J Surg
Pathol. 28:496–504. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Kim MS, In SG, Park OJ, et al: Increased
expression of activating transcription factor 3 is related to the
biologic behavior of cutaneous squamous cell carcinomas. Hum
Pathol. 42:954–959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Hai T and Hartman MG: The molecular
biology and nomenclature of the activating transcription
factor/cAMP responsive element binding family of transcription
factors: activating transcription factor proteins and homeostasis.
Gene. 273:1–11. 2001. View Article : Google Scholar
|
|
23.
|
Thompson MR, Xu D and Williams BR: ATF3
transcription factor and its emerging roles in immunity and cancer.
J Mol Med (Berl). 87:1053–1060. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Pelzer AE, Bektic J, Haag P, et al: The
expression of transcription factor activating transcription factor
3 in the human prostate and its regulation by androgen in prostate
cancer. J Urol. 175:1517–1522. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Bandyopadhyay S, Wang Y, Zhan R, et al:
The tumor metastasis suppressor gene Drg-1 down-regulates the
expression of activating transcription factor 3 in prostate cancer.
Cancer Res. 66:11983–11990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Ishiguro T, Nagawa H, Naito M and Tsuruo
T: Inhibitory effect of ATF3 antisense oligonucleotide on ectopic
growth of HT29 human colon cancer cells. Jpn J Cancer Res.
91:833–836. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Jang MK, Kim CH, Seong JK and Jung MH:
ATF3 inhibits adipocyte differentiation of 3T3-L1 cells. Biochem
Biophys Res Commun. 421:38–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Vita M and Henriksson M: The Myc
oncoprotein as a therapeutic target for human cancer. Semin Cancer
Biol. 16:318–330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Pelengaris S, Khan M and Evan GI:
Suppression of Myc-induced apoptosis in beta cells exposes multiple
oncogenic properties of Myc and triggers carcinogenic progression.
Cell. 109:321–334. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Shachaf CM, Kopelman AM, Arvanitis C, et
al: MYC inactivation uncovers pluripotent differentiation and
tumour dormancy in hepatocellular cancer. Nature. 431:1112–1117.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Yu D, Dews M, Park A, Tobias JW and
Thomas-Tikhonenko A: Inactivation of Myc in murine two-hit B
lymphomas causes dormancy with elevated levels of interleukin 10
receptor and CD20: implications for adjuvant therapies. Cancer Res.
65:5454–5461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Jain M, Arvanitis C, Chu K, et al:
Sustained loss of a neoplastic phenotype by brief inactivation of
MYC. Science. 297:102–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Leszczyniecka M, Roberts T, Dent P, Grant
S and Fisher PB: Differentiation therapy of human cancer: basic
science and clinical applications. Pharmacol Ther. 90:105–156.
2001. View Article : Google Scholar : PubMed/NCBI
|
